As the global economy mends, the 2021 growth of Glomerulonephritis Treatment will have significant change from previous year. According to our (LP Information) latest study, the global Glomerulonephritis Treatment market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Glomerulonephritis Treatment market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.
The United States Glomerulonephritis Treatment market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Glomerulonephritis Treatment market, reaching US$ million by the year 2028. As for the Europe Glomerulonephritis Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Glomerulonephritis Treatment players cover Achillion Pharmaceuticals Inc, Anthera Pharmaceuticals Inc, Biogen Inc, and Bristol-Myers Squibb Company, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Glomerulonephritis Treatment market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Home Care
Clinic
Hospital
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Takeda
Visterra Inc